The Conversation (0)
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2018
May. 30, 2018 08:55AM PST
Biotech InvestingSurface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter of 2018. As quoted in the press release: “2018 has already been an enormously productive year for Surface with the advancement of our lead program, SRF231, into clinical development and …
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter of 2018.
As quoted in the press release:
“2018 has already been an enormously productive year for Surface with the advancement of our lead program, SRF231, into clinical development and the completion of our IPO,” said Jeff Goater, chief executive officer of Surface Oncology. “In addition, we recently selected lead development candidates and initiated IND-enabling studies for our CD39 and IL-27 programs. We look forward to additional pipeline progress later this year, including the advancement of SRF373, targeting CD73, into clinical trials.”